Annovis Bio Inc Stock Price, News & Analysis

Annovis (NYSE: ANVS) announced two scientific presentations at the 18th Clinical Trials on Alzheimer’s Disease (CTAD), December 1–4, 2025 in San Diego.

Presentation P073 covers amyloid co-pathology and cognitive decline in buntanetap-treated Parkinson’s disease dementia patients, presented by Cheng Fang, Ph.D. Presentation P007 describes a double 6/18-month Phase 3 study testing symptomatic and potential disease‑modifying efficacy of buntanetap in Alzheimer’s disease, presented by Maria Maccecchini, Ph.D., President and CEO. Both talks highlight recent biomarker data and cognition findings the company says support buntanetap’s potential disease‑modifying activity.

Annovis (NYSE: ANVS) announced the FDA scheduled a Type C meeting in January 2026 to discuss the clinical development pathway for buntanetap in Parkinson's disease dementia (PDD). The company said the meeting will cover trial design, patient population, and a potential approval route.

Annovis also reaffirmed that its Phase 3 Alzheimer's disease trial is enrolling on plan with full FDA alignment on study design, endpoints, and population following an End-of-Phase 2 meeting in 2024. Management said the Phase 3 design could support two NDAs: one for symptomatic treatment and one for disease-modifying treatment.

Annovis (NYSE: ANVS) reported Phase 3 data in early Parkinson's disease (NCT05357989) showing buntanetap halted cognitive decline across the study population and produced the largest benefit in patients with mild dementia.

Approximately 25% of participants had amyloid co-pathology and experienced accelerated cognitive decline that was reversed by buntanetap. Treatment also produced measurable reductions in plasma pTau217, total tau, and brain-derived tau, biomarkers linked to Alzheimer’s pathology.

Full biomarker data will be presented at CTAD in San Diego, December 1–4, 2025.

Annovis Bio (NYSE: ANVS) provided corporate updates and third quarter 2025 financial results on November 12, 2025. Key clinical progress includes full activation of 84 Phase 3 AD sites, first patients completing 6-month treatment, and October biomarker data showing reductions in neuroinflammation and neurodegeneration versus placebo. The company published PK data for a new crystalline buntanetap form and transferred patents securing IP through 2046. Financially, cash totaled $15.3M as of September 30, 2025 (includes $6.0M and $3.4M offerings) funding operations to Q3 2026. Q3 R&D was $6.3M; G&A $1.1M; diluted net loss was $0.37 per share; shares outstanding were 20.2M.

Annovis (NYSE: ANVS) reported that all 84 Phase 3 sites for its pivotal early Alzheimer's trial are fully activated and enrolling across the U.S., with the first participants having completed the 6-month treatment milestone.

The study is now 25% complete toward a total enrollment target of 760 patients with biomarker-confirmed amyloid pathology. A symptomatic 6-month readout is on track for H2 2026, followed by an 18-month disease‑modifying assessment; participants completing 6 months continue blinded treatment for 12 more months.

Annovis Bio (NYSE: ANVS) announced a registered direct offering of 1,670,732 shares of common stock at $2.05 per share (closing price on Oct 24, 2025).

The offering is expected to close on or about October 28, 2025, with aggregate gross proceeds of approximately $3.4 million before placement agent fees and expenses. Michael Hoffman (board chair) and CEO Dr. Maria Maccecchini are participating in the purchase.

H.C. Wainwright & Co. is the exclusive placement agent. Net proceeds are intended for working capital and general corporate purposes. Securities are offered under a Form S-3 shelf registration (No. 333-276814) declared effective Feb 12, 2024.

Annovis (NYSE: ANVS) closed a registered direct offering on October 15, 2025 selling an aggregate of 4,000,000 shares (or pre-funded warrants) at $1.50 per share, generating approximately $6.0 million in gross proceeds before placement agent fees and offering expenses. H.C. Wainwright & Co. served as exclusive placement agent. The company intends to use net proceeds for working capital and general corporate purposes. The securities were offered under a Form S-3 shelf registration (No. 333-276814) declared effective Feb 12, 2024, and via a prospectus supplement filed with the SEC.

Annovis (NYSE: ANVS) entered into definitive agreements to sell an aggregate of 4,000,000 shares of common stock (or pre-funded warrants) at $1.50 per share in a registered direct offering, with expected gross proceeds of approximately $6 million. Closing is expected on or about October 13, 2025, subject to customary conditions. H.C. Wainwright & Co. is the exclusive placement agent. The company intends to use net proceeds for working capital and general corporate purposes. The offering is being made under a shelf registration (Form S-3, Reg. No. 333-276814) with a prospectus supplement to be filed with the SEC.

Annovis (NYSE: ANVS) reported novel biomarker results from its Phase 2/3 Alzheimer's study (NCT05686044) showing that buntanetap reduced inflammatory markers IL-5, IL-6, S100A12, IFN-γ, IGF1R and lowered NFL after three months. Responses were seen in all patients with positive pTau217, including mild and moderate stages. Company cites prior cognitive benefit in mild AD and notes buntanetap is being evaluated in a pivotal Phase 3 early AD trial (NCT06709014) with a 6-month symptomatic readout and an 18-month disease-modification readout. Full biomarker data will be presented at CTAD Dec 1-4, 2025.